Argitalpenak (34) VIRGINIA BELLIDO CASTAÑEDA argitalpenak

2023

  1. Changing trends in transgender demographics and morbidity: baseline data from a Spanish cohort

    Sexual health, Vol. 20, Núm. 1, pp. 96-98

  2. Comprehensive approach to people with type 2 diabetes. Diabetes Knowledge Area of the Spanish Society of Endocrinology and Nutrition

    Endocrinologia, Diabetes y Nutricion, Vol. 70, pp. 95-102

2022

  1. Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications

    Diabetes Therapy, Vol. 13, Núm. 5, pp. 873-888

  2. Description of a Cohort of Type 1 Diabetes Patients: Analysis of Comorbidities, Prevalence of Complications and Risk of Hypoglycemia

    Journal of Clinical Medicine, Vol. 11, Núm. 4

  3. Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study

    Drugs in Context, Vol. 11

  4. Flash Glucose Monitoring and Diabetes Mellitus Induced by Immune Checkpoint Inhibitors: An Approach to Clinical Practice

    Journal of Diabetes Research, Vol. 2022

  5. Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study

    Journal of Clinical Medicine, Vol. 11, Núm. 17

2021

  1. Covid-19 and diabetes

    Journal of Clinical Medicine, Vol. 10, Núm. 22

  2. DAPA-RWE: A retrospective multicenter study comparing dapagliflozin and sitagliptin in patients with Type 2 diabetes treated under routine clinical practice in Spain

    Journal of Comparative Effectiveness Research, Vol. 10, Núm. 10, pp. 815-821

  3. Effectiveness of two procedures for deploying a facilitated collaborative modeling implementation strategy—the PVS-PREDIAPS strategy—to optimize type 2 diabetes prevention in primary care: the PREDIAPS cluster randomized hybrid type II implementation trial

    Implementation Science, Vol. 16, Núm. 1

  4. Inpatient Hyperglycemia Management and COVID-19

    Diabetes Therapy, Vol. 12, Núm. 1, pp. 121-132

  5. The Challenge of Sustainable Access to Telemonitoring Tools for People with Diabetes in Europe: Lessons from COVID-19 and Beyond

    Diabetes Therapy, Vol. 12, Núm. 9, pp. 2311-2327

  6. Time-in-range for monitoring glucose control: Is it time for a change?

    Diabetes Research and Clinical Practice, Vol. 177

2020

  1. A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe

    DIABETES THERAPY, Vol. 11, Núm. 2, pp. 423-436

  2. Clinical Approach to Flash Glucose Monitoring: An Expert Recommendation

    Journal of Diabetes Science and Technology

  3. Consequences of COVID-19 on people with diabetes

    Endocrinologia, Diabetes y Nutricion, Vol. 67, Núm. 6, pp. 355-356

  4. Cost analysis of the flash monitoring system (FreeStyle Libre 2) in adults with type 1 diabetes mellitus

    BMJ Open Diabetes Research and Care, Vol. 8, Núm. 1

  5. Effectiveness of sulfonylurea treatment in a patient with a mutation in ABCC8 (MODY12)

    Endocrinologia, Diabetes y Nutricion, Vol. 67, Núm. 10, pp. 682-683

  6. Impact of COVID-19 lockdown on glycemic control in patients with type 1 diabetes

    Diabetes Research and Clinical Practice, Vol. 166

  7. Update on postprandial hyperglycaemia: the pathophysiology, prevalence, consequences and implications of treating diabetes

    Revista Clinica Espanola, Vol. 220, Núm. 1, pp. 57-68